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Abstract
Despite the success of antiretroviral therapy (ART) in decreasing mortality for HIV-1-infected patients, ART has
not cured the disease. A persistent viral reservoir in the T cells of HIV patients receiving potent ART is a
significant barrier preventing eradication of HIV infection. We will briefly review what is known about the
mechanisms that establish and maintain persistent HIV infection despite ART, to create a framework in which to
consider approaches to the clearance or eradication of infection (‘‘cure’’), or to allow clinical stability in the
absence of ART (‘‘functional cure’’). With regard to eradication therapies, it could be said that as a field our
position is analogous to that of ART early in the HIV pandemic. As then we must now simultaneously develop
and optimize platforms and paradigms for the discovery and testing of eradication therapies, and begin to
advance candidate therapies toward human testing.
Introduction
Successful antiretroviral therapy (ART) often resultsin clinical stability and plasma levels of HIV-1 RNA below
the limits of detection in routine assays. Despite the success of
ART, more people contract human immunodeficiency virus
(HIV) infection daily than initiate ART. The difficulties of
lifelong ART––particularly in the developing world––have
recently stimulated a reevaluation of approaches to the
eradication of HIV infection.
The inability of ART to eradicate HIV was first suggested
by the demonstration of latent infection of resting CD4 + T
cells,1 and then demonstrated by the recovery of rare, inte-
grated, replication-competent HIV from the resting CD4 +
memory T cells of patients receiving potent ART.2–4 To date,
this reservoir remains the most widely studied and best un-
derstood cause of viral persistence. Evidence suggests that the
resting T cell reservoir is established early after infection and
is extremely stable.5,6 Current ART does not eradicate HIV
infection, as these latently infected cells remain persistently
infected and unrecognized by the immune system, with
minimal expression of HIV genes or proteins.7 It appears that
the persistence of quiescent HIV infection, primarily within
central memory T cells, is currently the major obstacle to
eradication of HIV infection. This is a scientific hurdle that has
yet to be overcome, as we completely lack the ability to
therapeutically target proviral HIV genomes that express little
or no HIV RNA or protein.
Furthermore, in a substantial proportion of treated patients
very low levels of viral RNA can be detected by research
assays.8–11 This low-level viremia does not appear to lead to
drug resistance or failure of therapy, and appears to represent
expression of viral particles without effective rounds of new
replication,12,13 but is nevertheless a potential additional ob-
stacle to viral eradication.
Finally, other reservoirs of persistent infection despite ART
have been reported that could reignite HIV infection. These
reservoirs have not been defined as well in patients on suc-
cessful, suppressive ART. Naive T cells have been suggested
to harbor persistent replication-competent HIV, but the fre-
quency of these cells appears low.14 Macrophages have long
been identified as another cell type capable of supporting
persistent infection despite ART. Macrophages and mono-
cytes are long-lived cells that may serve as potential sites of
persistent viral expression, surviving with ongoing low levels
of virus release in patients on ART.15,16 A minor subset of
CD16 + monocytes has been shown to be more permissive to
HIV-1 replication compared with the major CD14highCD16 -
compartment, and HIV-1 was identified within the CD16 +
monocytes of patients after full suppression on HAART.17
However, it has yet to be clearly documented that these cells
carry quiescent provirus in vivo for many months, as can
resting CD4 + T cells. This is an important distinction, as viral
persistence in a cell that is expressing viral proteins or parti-
cles may be addressed by improvements in ART or the anti-
viral immune response. Recent reports have demonstrated the
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recovery of replication-competent HIV immediately post-
mortem from follicular dendritic cells in patients on ART18
and suggested that hematopoietic stem cells are a source
of persistent HIV.19 However, these observations are contro-
versial.20,21
The clearance of a retroviral infection in patients on ART
is therefore a herculean task. While much is known about
HIV persistence despite ART, many puzzles remain. Of
even greater significance, while the clinical development path
for antiviral therapies is well trodden, and paradigms for
studying preventive microbicides or vaccines are being de-
veloped, a validated framework for inventing and testing
eradication therapies does not exist.
Mechanisms of Persistent HIV Infection
Over the past two decades, a wealth of knowledge has been
uncovered to explain the mechanisms that drive the HIV in-
fection and viral production, and that rarely allow latent
proviral infection to develop and persist. For the purposes
of this discussion, we define quiescent but replication-
competent provirus as proviral latency. In our view, such latent
infection is clearly defined and quantified in resting CD4 + T
lymphocytes, and while it may persist in cells that are not
CD4 + T cells, this has yet to be carefully and longitudinally
quantified in effectively treated patients. Measures of viral
DNA in various cell populations likely dramatically overesti-
mate the frequency of viral genomes that are capable of repli-
cating and reigniting infection. On the other hand, quantitation
of replication-competent virus is laborious and may underes-
timate the true frequency of such genomes in vivo. As with so
many things, the truth likely lies in between.
Nevertheless, it cannot be overemphasized that the per-
sistence of HIV infection despite ART is not a unidimensional
problem. While proviral latency is clearly a central problem,
the origin of persistent production of HIV RNA that can be
detected in plasma of HIV-infected patients on durably suc-
cessful ART by research assays is yet to be fully explained.22
This expression of viral particles appears to occur without
evidence of full rounds of replication,12,13 as this would in-
evitably select for ART resistance. It is incompletely under-
stood how expression may persist on ART without the
development of drug resistance. One explanation is that
persistent production of HIV RNA originates exclusively in
cells that were infected prior to ART initiation. Another ex-
planation is that complete replication events occur below the
frequency required for the emergence and subsequent selec-
tion of drug-resistant genomes. The first explanation begs the
question of where all the cells capable of producing a steady
but low level of plasma viremia for months or years are
hiding. The second explanation seems increasingly unlikely
in the face of an expanding number of patients who remain
suppressed on therapy for years without the noticeable ap-
pearance of patients with spontaneous, unexplained drug
failure.
Finally, low levels of cell-free or cell-associated HIV RNA
have been measured or observed in tissue, such as the GALT
(gut-associated lymphoid tissue) or central nervous sys-
tem.23,24 It is not clear whether these observations represent
(1) anatomic regions or cellular compartments that are sanc-
tuaries in which complete cycles of ongoing replication are
incompletely blocked by ART, or (2) transient bursts of viral
production originating from resident but previously latently
infected cells, or from latently infected cells or virions in
transit through this compartment that will fail to result in
ongoing replication due to the presence of ART.
Mechanisms of Proviral Latency
The activity of the viral long terminal repeat (LTR) pro-
moter of the HIV-1 is the stage on which the drama of the
host–virus interaction is played out, leading to latency or
production, as HIV co-opts numerous cellular factors to con-
trol the rate of viral transcript production.25 In addition to
cellular factors that bind LTR DNA sequences, acting as
classical cis regulators, the viral transactivator Tat binds to
TAR, the viral leader messenger RNA (mRNA) sequence that
serves as a unique target in the regulation of LTR transcrip-
tion. In most settings, HIV rapidly appropriates the resources
of the activated CD4 + T cell to transform it into a factory for
virus production.
However, should factors that assist in HIV transcription,
the production of the viral Tat activator, and the subsequent
action of Tat be even transiently deficient, this presents an
opportunity for factors that antagonize HIV expression to
exert their effect, dampening HIV expression. Over time, these
factors may establish restrictions on HIV expression that are
increasingly potent and durable. Here we highlight the basic
mechanisms for the establishment and maintenance of viral
reservoirs within resting CD4 + T cells, mechanisms that may
be targets for therapeutics to disrupt latency and eliminate
persistent infection.
It is the down-regulation of expression of the HIV-1
genome that plays a pivotal role in the establishment of the
rare latent stage of the life cycle of this pathogenic retrovirus.
Latency may be established (1) by direct albeit inefficient,
infection of resting memory cells, (2) by the infection of T cells
just prior to their natural reversion to a quiescent state, as with
memory T cells, or (3) in the case of the naive T cell population,
infection of cells that are undergoing differentiation during
thymopoiesis. Given the potency of the viral transactivator
Tat, and the responsiveness of the HIV promoter to many
cellular activating signals, counterregulatory mechanisms
that repress transcription appear to be required to allow HIV
to establish or maintain a persistent, nonproductive infection.
Low nuclear levels of the coactivating factors nuclear factor
(NF)-jB and nuclear factor of activated T cells (NFAT) are a
feature of resting CD4 + cells, and may set the stage for the
establishment of latency.23 Naturally low levels of the P-TEFb
component CycT1 and sequestration of the P-TEFb complex
by the HEXIM/7SK RNA complex in resting lymphocytes
present an additional restriction to viral expression in this
cellular milieu. Posttranscriptional mechanisms may also
pose a barrier to expression of provirus in resting cells.26–28
Recent data have enhanced the argument that transcriptional
interference mediated by nearby host gene promoters con-
tributes to the quiescence of some HIV proviral genomes,29–31
a concept observed because most viral integrants reside in
introns of actively transcribed genes.16 Finally, modeling
studies suggest that stochastic, transient deficiencies in the
availability of the viral Tat transactivator could allow the viral
promoter to slip down into a kinetic well of repressed ex-
pression, where counterregulatory cellular influences enforce
repression and silence the provirus.32
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Posttranslational histone modifications, previously re-
ferred to as the ‘‘histone code,’’ are distinct modifications oc-
curring at particular sites on the histone tail that can direct
protein complexes to interact with the histone–DNA multi-
mer, directing gene activity.33 These modifications may in
general make chromatin more or less accessible to transcrip-
tion factors, but also form biophysical marks on genes that
signal the ordered recruitment of complexes of regulatory
factors that up- or down-regulate gene expression. Such epi-
genetic histone markings appear to play a key contributory
role in regulating HIV expression, and in particular in estab-
lishing LTR quiescence and latency. Furthermore, to add an-
other layer of complexity, many of the host enzymes that
modify histones also modify other cellular proteins, and so the
regulatory network that may down-modulate HIV gene ex-
pression may be linked to other biochemical cellular events
that enforce HIV latency.34,35
Initial studies by Verdin demonstrated that a strictly posi-
tioned nucleosome (Nuc-1) was found at the viral RNA start
site ( + 10 to + 155), and increased accessibility of chromatin
near Nuc-1 associated with transcriptional activation.
Furthermore, histone deacetylase inhibitors were shown to
up-regulate LTR expression.36,37 Later, recruitment and oc-
cupancy of histone deacetylase 1 (HDAC1) at the HIV LTR
were shown to directly mediate transcriptional silencing.38–40
Further study of the role of HDACs in LTR regulation re-
vealed multiple cellular DNA-binding protein complexes that
could recruit HDACs to the integrated provirus.41–45
Recently it has been found that the class I HDACs 1, 2, and 3
predominate at the HIV LTR in CD4 + T cell models, and that
viral outgrowth could be induced from the resting CD4 + T
cells of HIV-infected, aviremic, ART-treated patients by se-
lective HDAC inhibitors (HDACis) targeting these same class
I HDACs.46–52 Other epigenetic modifications, such as meth-
ylation of histones or of DNA itself, contribute to the regula-
tion of proviral latency, and may be targets for therapy. CpG
methylation of HIV promoter DNA has been shown to con-
tribute to establish a durable, ‘‘locked’’ state that is difficult to
reactivate. Histone methyltransferases such as EZH2 and
SUV39H1 can regulate HIV-1 transcription by inducing his-
tone H3 at lysine 9 (H3K9) methylation, and other repres-
sive proteins can accumulate on transcriptionally inactive
proviruses.53–56 Pearson and colleagues further corroborated
those findings and showed that progressive iterative histone
modifications drive a proviral promoter into latency in pri-
mary CD4 + T cells.57
Further restrictions to proviral expression and the escape
from latency may exist beyond the step of the production of
the initial viral mRNA transcripts. Host enzymes may inhibit
the activity Tat protein that is produced by any initial burst of
viral expression, raising another obstacle to the escape from
latency.58,59 HIV mRNA export may be impaired in resting
T cells, posing another barrier to production of provirus.28
Host miRNAs may also impede HIV mRNA expression or
translation.26,27
Overall, the view of the establishment and maintenance of
latent proviral infection is one of a dynamic process in which
latency is established by a series of or accumulation of infre-
quent events. However, once established, expression of the
proviral promoter is then restricted on numerous levels. The
first translational challenge is to develop approaches that
are capable of safely and effectively overcoming the obstacles
to proviral production. This in and of itself may allow purging
of the persistent proviral reservoir, or an alterative additional
step may need to be taken to ensure the clearance of pro-
ductively infected cells.
Source(s) of Persistent Production
Paradoxically, in the majority of patents on fully suppres-
sive ART in whom latently infected resting CD4 + T cells can
be routinely measured, the baffling phenomenon of persis-
tent, low-level viremia can be observed in parallel. Initially, it
was assumed that this viremia originated when latently in-
fected resting memory cells were periodically activated, un-
dergoing proliferation and high-level virion production.
However, one study suggests that this chronic production of
HIV RNA may not originate entirely from the resting CD4 +
T cell reservoir,60 and in some patients viral sequences found
in circulating viral particles could not be found within resting
CD4 + T cells. A follow-up study found that residual viremia
was genetically distinct from proviruses in activated CD4 +
T cells, monocytes, and unfractionated peripheral blood
mononuclear cells.61 In another study phylogenetic analysis
of low-level viremia in four of five patients showed that these
viral species were genetically distinct from most species found
in CD4 + cells.62 However, in the absence of the identification
of the cellular source of residual viremia despite ART, these
observations can only be suggestive rather than definitive.
Alternatively, a subpopulation of CD4 cells that was not
captured for analysis could be the source of residual viremia.
In preliminary studies, single-genome analysis of circulating
viral species in residual viremia in two patients suppressed on
ART was identical to that found in resting CD4 + T cells, but
found only when replication-competent viruses were recov-
ered from millions of resting CD4 + cells.63 If novel cell type(s)
are the source(s) of persistent viremia, they have yet to be
definitively identified.
Maintenance of the Latent Pool
A recent, alternative model of persistent infection, not ex-
clusive of the mechanisms discussed above, implies that
proviral infection is not completely stable, and that while in-
fected resting cells leave the quiescent memory pool at a
steady rate, the frequency of infection in this pool of cells is
maintained by homeostatic proliferation of infected cells.64
This is an important new concept, and is consistent with
general concepts of immunological memory. Although the
numbers of cells available in this first study were too limited
to perform robust quantitation of replication-competent virus
with memory cell populations, it was suggested that central
(TCM) and transitional memory (TTM) CD4
+ T cells are the
major cellular reservoirs in which integrated HIV DNA per-
sists. In this model in stable patients on ART, CD4 + depletion
could drive interleukin (IL)-7-mediated homeostatic prolifer-
ation, allowing host-driven replication of proviral genomes
without the death of these infected cells, ensuring the persis-
tence of this reservoir. It was hypothesized that the relative
burden of latent infection in these cell subpopulations may
depend on the stage of disease in which ART was initiated.
This model would require close matching of the rates of in-
fected memory cell activation and of homeostatic prolifera-
tion, as in most studies the size of this pool of infected cells is
stable, regardless of the stage of disease at which the patient
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was treated. Clearly this issue requires further study, as
therapies designed to target proviral genomes might perform
differently in TCM or TTM cells.
Translating Mechanisms to Therapies:
Creating a Development Pathway
As can readily be seen in the above discussion, a great deal
is known about persistent HIV infection and proviral latency,
specifically in various in vitro and ex vivo biological systems.
However, it has been difficult to translate this progress into
therapies that might eradicate established HIV infection.
While there is unanimity in scientific opinion that there is no
effective cure for HIV infection on the horizon, until recently
little concerted effort has been directly devoted to this sig-
nificant challenge. To create both the scientific and transla-
tional infrastructure to support a serious and sufficiently
durable effort to eradicate HIV infection, an investment is
needed in three critical areas: (1) a better understanding of the
biological complexity of HIV and the factors that drive per-
sistent infection; (2) improvements in the cell and animal
model systems to provide a fuller representation of persistent
HIV infection in the setting of ART; and (3) improved assays
to ameliorate the challenges of translational studies seeking to
deplete persistent infection.
Given the several mechanisms that drive proviral latency
identified, the time would seem ripe for careful translational
studies designed to target these mechanisms, perturb latency,
and carefully measure the results of these translational ap-
proaches. HDACs are clearly a potentially useful target in this
regard. Suberoylanilide hydroxamic acid (SAHA), an HDAC
inhibitor with nanomolar potency selective for the crucial Class
I HDACs, has been shown to induce the expression of latent
HIV ex vivo from the resting CD4 + T cells of HIV-infected,
ART-treated, aviremic patients at a concentration of protein-
unbound drug that is achieved with clinical dosing.48–50 Our
group has received FDA approval for a clinical experiment in
humans to directly test the hypothesis that a clinically tolerable
dose of SAHA can induce expression of HIV within resting
CD4 + T cells in vivo, and to investigate the safety, tolerability,
and spectrum of side effects of a limited exposure to SAHA in
combination with ART. This proof-of-concept study may allow
for optimization of advanced assays to measure effects on
latent HIV infection, and provide evidence that HDACis can
perturb persistent HIV infection.
However, SAHA is a mutagen in vitro in standard bacterial
assays, and so prolonged exposure in a clinical trial is currently
unacceptable. Furthermore, a direct demonstration of the de-
sired antilatency effect of HDAC inhibitors in vivo––induction
of HIV expression–may alone not be sufficient to result in the
clearance of infected cells. Several reports have recently sug-
gested combinatorial strategies to effectively and comprehen-
sively purge the pool of replication-competent, integrated,
persistent HIV.54,55,65–69 Concepts proposed include combining
SAHA with the inhibition of histone and/or DNA methylation,
or with various cellular signaling or activating pathways. For
example, a novel protein kinase agonist, bryostatin, now under
study in Alzheimer’s disease, can reactivate latent HIV-1.68,69
Bryostatin was also synergistic when tested in combination
with HDACis, and was found to downregulate the expression
of the HIV-1 coreceptors CD4 and CXCR4 and prevented de
novo HIV-1 infection in susceptible cells.
When comparing the potential of different compounds or
different approaches to deplete persistent proviral infection,
several caveats bear consideration:
1. Are drugs or combinations that induce a higher level of
HIV gene expression more desirable than those that induce
less robust expression of latent provirus? Clearly some
threshold must be exceeded if an approach is to be
sufficiently potent to be effective, but at what level will
virion production lead to spreading infection despite
the presence of ART?
2. What concentrations of drug, alone or in combination, can be
achieved in vivo? Pharmacokinetic and pharmacody-
namic information, and considerations of free and
protein-bound drug in vitro and in vivo, are important.
3. How long and at what level must these exposures be main-
tained to be effective? It is difficult to model the temporal
dynamics of drug activity in vivo in cell culture systems.
4. What are the temporal effects of single exposures, and
repeated exposure to reagents that perturb latency? If com-
binations of drugs are given, must they be given simulta-
neously?
5. How can we be sure that virus will be cleared once its pro-
viral latency is interrupted? This is a critical question that
must be addressed, but perhaps can be addressed only
once antilatency therapies are in place. If viral replica-
tion does not result in the clearance of infected cells,
strategies to augment the immune response or the use
of agents that induce the death of such productively
infected cells may have to be developed and employed.
While combination approaches to perturbing latent infec-
tion may be mechanistically valid in experimental systems,
given the clinical challenges of testing a single HDACi such as
SAHA, combination approaches will be difficult to test in
clinical trials. Given the success of current ART and the rela-
tive good health and significant life expectancy of patients
with stably suppressed viremia, it is crucial that clinical ap-
proaches to eradication be safe and tolerable.
The fact that in vitro efficacy has not yet translated into
success in the clinical setting highlights the need for the de-
velopment of a larger and more complex substrate for latency
studies than offered by in vitro models currently in use. The
complexity of HIV-1 persistence and latency requires animal
models for assessing and optimizing eradication therapies
that activate latent virus and then evaluate potential toxicities
to accelerate their use either singly or in combination in hu-
man clinical trials. Currently, the most advanced models
available appear to be the SIV nonhuman primate (NHP) and
humanized bone marrow-liver-thymus (BLT) mouse.70–77
Optimization of ART regimens may be required to ideally
reflect current human therapy.
However, animal models provide several key advantages.
While residual plasma viremia can be quantitated effectively
in humans, measurement of residual viremia in tissues is im-
practical and in many tissues impossible; thus, residual vire-
mia in lymphoid organs, central nervous system, and GALT
may be evaluable only in animal models. Latency in resting
CD4 + T cells has been well characterized in plasma and
lymph nodes in HIV-infected humans. However, the level of
latently infected CD4 + T cells in other tissues remains to be
studied. In addition, the level of viral latency in monocytes
in plasma and macrophages in tissues is largely unknown.
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Latency in macrophages can be characterized in both the SIV
macaque model and BLT mice. It will be essential in these
animal models to induce activation of latent virus and then
withdraw ART to examine whether and when virus re-
activation occurs compared to ART-treated animals without
virus activation. Obviously, such experiments cannot be
performed in HIV-infected individuals who have controlled
virus replication on ART. Finally, such systems permit the
study of pharmacological questions.
The Road Ahead
Few scientific and medical challenges are as daunting and
complex as curing HIV infection. As we renew efforts to fur-
ther understand viral persistence, and bring these insights to
bear toward the ultimate goal of HIV eradication, additional
obstacles to clearance of HIV infection are likely to be un-
covered. The progress made so far in gaining a detailed
understanding of HIV biology and pathogenesis and the
stunning achievements of ART should give us hope that we
can overcome the recognized and the yet-to-be-discovered
challenges of persistent HIV infection. It is time to begin again
in earnest.
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